Business Context and Reporting Period
Company: Ligand Pharmaceuticals Incorporated (LGND)
Filing Type: Form 8-K (Current Report)
Date of Report: May 7, 2026
Reporting Period: Three months ended March 31, 2026
Context: The filing announces the issuance of a press release containing financial results for the first quarter of 2026. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are located in the referenced press release (Exhibit 99.1), which is not included in the input text. Therefore, no specific values can be reported from this document.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms that results for the three months ended March 31, 2026, have been announced.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release for management commentary but does not include the text of that commentary.
Legal Disclaimer: The filing explicitly states that the information, including the press release, is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liability of that section, nor is it incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 7, 2026) for specific Q1 2026 revenue, net income, and cash flow figures.
- Verify year-over-year comparisons and margin trends in the full press release.
- Check for updated forward-looking guidance or clinical trial milestones mentioned in the press release.
- Confirm the status of the company's liquidity and debt obligations as detailed in the full financial disclosure.